Summit Therapeutics
37
24
26
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
5.4%
2 terminated/withdrawn out of 37 trials
71.4%
-15.1% vs industry average
19%
7 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Role: collaborator
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Role: collaborator
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Role: collaborator
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Role: lead
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Role: collaborator
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Role: collaborator
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Role: collaborator
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Role: collaborator
Phase III Study of AK112 for NSCLC Patients
Role: lead
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Role: lead
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Role: collaborator
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Role: collaborator
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Role: collaborator
Ivonescimab for the Treatment of Thymic Cancer
Role: collaborator
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
Role: collaborator
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Role: collaborator
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Role: collaborator
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Role: collaborator
A Study of Ivonescimab in People With Leiomyosarcoma
Role: collaborator
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Role: collaborator